JP2018529661A - ループス腎炎の処置のための抗ｃｄ４０抗体の使用 - Google Patents

ループス腎炎の処置のための抗ｃｄ４０抗体の使用 Download PDF

Info

Publication number
JP2018529661A
JP2018529661A JP2018511144A JP2018511144A JP2018529661A JP 2018529661 A JP2018529661 A JP 2018529661A JP 2018511144 A JP2018511144 A JP 2018511144A JP 2018511144 A JP2018511144 A JP 2018511144A JP 2018529661 A JP2018529661 A JP 2018529661A
Authority
JP
Japan
Prior art keywords
seq
antibody
sequence
light chain
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018511144A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018529661A5 (enExample
Inventor
ブロデューア，スコット・ロナルド
フリーマン，トーマス・ビー
ナバズニー，ジェラルド・ヘンリー
ラマヌジャン，ミーラ
ショール，ポール
シュテッフゲン，ユルゲン
Original Assignee
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング, ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング filed Critical ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Publication of JP2018529661A publication Critical patent/JP2018529661A/ja
Publication of JP2018529661A5 publication Critical patent/JP2018529661A5/ja
Priority to JP2021134828A priority Critical patent/JP2021185169A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018511144A 2015-09-01 2016-08-31 ループス腎炎の処置のための抗ｃｄ４０抗体の使用 Pending JP2018529661A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021134828A JP2021185169A (ja) 2015-09-01 2021-08-20 ループス腎炎の処置のための抗ｃｄ４０抗体の使用

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562212810P 2015-09-01 2015-09-01
US62/212,810 2015-09-01
US201562257336P 2015-11-19 2015-11-19
US62/257,336 2015-11-19
US201662287587P 2016-01-27 2016-01-27
US62/287,587 2016-01-27
PCT/US2016/049558 WO2017040566A1 (en) 2015-09-01 2016-08-31 Use of anti-cd40 antibodies for treatment of lupus nephritis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021134828A Division JP2021185169A (ja) 2015-09-01 2021-08-20 ループス腎炎の処置のための抗ｃｄ４０抗体の使用

Publications (2)

Publication Number Publication Date
JP2018529661A true JP2018529661A (ja) 2018-10-11
JP2018529661A5 JP2018529661A5 (enExample) 2019-10-10

Family

ID=56896810

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018511144A Pending JP2018529661A (ja) 2015-09-01 2016-08-31 ループス腎炎の処置のための抗ｃｄ４０抗体の使用
JP2021134828A Pending JP2021185169A (ja) 2015-09-01 2021-08-20 ループス腎炎の処置のための抗ｃｄ４０抗体の使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021134828A Pending JP2021185169A (ja) 2015-09-01 2021-08-20 ループス腎炎の処置のための抗ｃｄ４０抗体の使用

Country Status (16)

Country Link
US (3) US20170058038A1 (enExample)
EP (1) EP3344655B1 (enExample)
JP (2) JP2018529661A (enExample)
KR (1) KR20180039172A (enExample)
CN (1) CN107922501A (enExample)
AU (1) AU2016317028B2 (enExample)
BR (1) BR112018001907A2 (enExample)
CA (1) CA2993996A1 (enExample)
CL (1) CL2018000317A1 (enExample)
DK (1) DK3344655T5 (enExample)
ES (1) ES2969968T3 (enExample)
HU (1) HUE063528T2 (enExample)
MX (1) MX390653B (enExample)
PH (1) PH12018500445B1 (enExample)
PL (1) PL3344655T3 (enExample)
WO (1) WO2017040566A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018076260A2 (pt) 2016-06-20 2019-03-26 Kymab Limited anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
IL270596B1 (en) * 2017-05-25 2025-09-01 Bristol Myers Squibb Co Antibodies comprising modified heavy constant region for use in treating cancer
JP7504808B2 (ja) * 2018-06-29 2024-06-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 自己免疫疾患の処置における使用のための抗ｃｄ４０抗体
CN112839961B (zh) * 2018-11-30 2023-04-04 江苏恒瑞医药股份有限公司 一种cd40抗体药物组合物及其用途
HRP20250696T1 (hr) 2021-01-28 2025-08-01 Regeneron Pharmaceuticals, Inc. Sastavi i postupci za liječenje sindroma oslobađanja citokina
WO2025184567A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
US20250277048A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008509080A (ja) * 2004-04-27 2008-03-27 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド アンタゴニスト抗ｃｄ４０モノクローナル抗体およびその使用方法
JP2009534401A (ja) * 2006-04-21 2009-09-24 ノバルティス アーゲー 拮抗剤抗ｃｄ４０抗体薬学的組成物
JP2013523130A (ja) * 2010-03-31 2013-06-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗ｃｄ４０抗体

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP0656789B1 (en) 1992-08-21 1997-12-17 Genentech, Inc. Method for treating a lfa-1-mediated disorder
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
US20030059427A1 (en) * 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
US8277810B2 (en) * 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
ATE485057T1 (de) * 2005-05-26 2010-11-15 Seattle Genetics Inc Humanisierte antikörper gegen cd40 und verfahren zu ihrer anwendung
CN103635488B (zh) * 2011-04-29 2016-12-14 埃派斯进有限公司 抗-cd40抗体及其使用方法
US20140004131A1 (en) * 2012-05-04 2014-01-02 Novartis Ag Antibody formulation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008509080A (ja) * 2004-04-27 2008-03-27 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド アンタゴニスト抗ｃｄ４０モノクローナル抗体およびその使用方法
JP2009534401A (ja) * 2006-04-21 2009-09-24 ノバルティス アーゲー 拮抗剤抗ｃｄ４０抗体薬学的組成物
JP2013523130A (ja) * 2010-03-31 2013-06-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗ｃｄ４０抗体

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MOHAN C; ET AL: "INTERACTION BETWEEN CD40 AND ITS LIGAND GP39 IN THE DEVELOPMENT OF MURINE LUPUS NEPHRITIS", THE JOURNAL OF IMMUNOLOGY, vol. VOL:154, NR:3, JPN5018005634, 1995, US, pages 1470 - 1480, ISSN: 0004489339 *
PLOS ONE, vol. Vol.8, No.6, e65068, JPN6020033276, 2013, pages 1 - 13, ISSN: 0004489338 *

Also Published As

Publication number Publication date
HUE063528T2 (hu) 2024-01-28
CL2018000317A1 (es) 2018-07-20
US20190177420A1 (en) 2019-06-13
ES2969968T3 (es) 2024-05-23
BR112018001907A2 (pt) 2018-09-25
CN107922501A (zh) 2018-04-17
AU2016317028A1 (en) 2018-02-22
AU2016317028B2 (en) 2021-09-09
MX390653B (es) 2025-03-21
MX2018002447A (es) 2018-06-15
PH12018500445A1 (en) 2018-09-10
PH12018500445B1 (en) 2022-08-10
DK3344655T3 (da) 2023-10-09
DK3344655T5 (da) 2024-10-07
WO2017040566A1 (en) 2017-03-09
PL3344655T3 (pl) 2024-02-19
US20170058038A1 (en) 2017-03-02
US20230265203A1 (en) 2023-08-24
EP3344655B1 (en) 2023-07-26
CA2993996A1 (en) 2017-03-09
KR20180039172A (ko) 2018-04-17
JP2021185169A (ja) 2021-12-09
EP3344655A1 (en) 2018-07-11

Similar Documents

Publication Publication Date Title
US20230265203A1 (en) Use of anti-cd40 antibodies for treatment of lupus nephritis
AU2018311079B2 (en) Interleukin-21 muteins and methods of treatment
JP5752865B1 (ja) 抗ｃｄ４０抗体
JP5933646B2 (ja) ヒトｎｋｇ２ｄに対する抗体とその使用
US9260515B2 (en) Antibodies to human GDF8
KR102391338B1 (ko) 항-pd-1 항체
KR20200110358A (ko) 항-pd-1 항체 및 치료 방법
US20240287198A1 (en) Anti-cd40 antibodies for use in prevention of graft rejection
JP2011523414A (ja) 抗ｆｎ１４抗体、およびその使用
JP2008501712A (ja) 多発性硬化症を処置するための方法
CN106414489A (zh) 抗-b7-h5抗体及其用途
JP2017505622A (ja) 新規な抗ｂａｆｆ抗体
CN112334195A (zh) 用于治疗自身免疫性疾病的抗cd40抗体
CN111511760A (zh) 对btn2具有特异性的抗体及其用途
CN116323668A (zh) 治疗性抗体及其用途
JP2023123521A (ja) 多発性硬化症を治療するための方法
US20240209095A1 (en) Anti-human pd-l1 antibodies and their uses
EA039944B1 (ru) Применение антител к cd40 для лечения волчаночного нефрита

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190830

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190830

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200908

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201208

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210420